期刊文献+

Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis 被引量:7

Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis
下载PDF
导出
摘要 AIM: To elucidate the influences of Hpylori infection on oral iron treatment for iron deficiency anemia (IDA).METHODS: A total of 86 patients were divided into two groups: group A, receiving ferrous succinate combined with triple therapy for H pylori eradication, and group B (control), treated with ferrous succinate only. During treatment of IDA, dynamic changes in hemoglobin (Hb) level, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), serum iron (SI), and serum ferritin (SF) were compared between the groups.RESULTS: Hb was slightly higher in group A at d 14 alter the start of triple therapy for H pylori eradication (P 〉 0.05). After the therapy, the increase of Hb in group A became significantly faster than that in group B (P 〈 0.05). At d 56, the mean Hb in group A returned to the normal level, however, in group B, it was lower than that in group A (P 〈 0.05) although it had also increased compared with that before oral iron treatment. The MCV and MCH in group A recovered to the normal level, and were much higher than those in group B (P 〈 0.05) at d 21. In Group B, the MCV and MCH remained at lower than normal levels until d 42 alter the start of therapy. And then, they reached a plateau in both groups and the differences disappeared (P 〉 0.05). The SF in group A was higher than that in group B (P 〈 0.05) 28 d alter the treatment and its improvement was quicker in group A (P 〈 0.05), and the difference between the two groups was even more significant (P 〈 0.01) at d 56. The SI in group A was higher than that in group B (P 〈 0.05) at d 14 and this persisted until d 56 when the follow-up of this research was finished.CONCLUSION: Treatment of H pylori can enhance the efficacy of ferrous succinate therapy in IDA patients with Hpylori-positive chronic gastritis. AIM:To elucidate the influences of H pylori infection on oral iron treatment for iron deficiency anemia(IDA). METHODS:A total of 86 patients were divided into two groups:group A,receiving ferrous succinate combined with triple therapy for H pylori eradication,and group B(control),treated with ferrous succinate only.During treatment of IDA,dynamic changes in hemoglobin(Hb) level,mean corpuscular volume(MCV),mean corpuscular hemoglobin(MCH),serum iron(SI),and serum ferritin (SF)were compared between the groups. RESULTS:Hb was slightly higher in group A at d 14 after the start of triple therapy for H pylori eradication (P>0.05).After the therapy,the increase of Hb in group A became significantly faster than that in group B (P<0.05).At d 56,the mean Hb in group A returned to the normal level,however,in group B,it was lower than that in group A(P<0.05)although it had also increased compared with that before oral iron treatment.The MCV and MCH in group A recovered to the normal level,and were much higher than those in group B(P<0.05)at d 21.In Group B,the MCV and MCH remained at lower than normal levels until d 42 after the start of therapy. And then,they reached a plateau in both groups and the differences disappeared(P>0.05).The SF in group A was higher than that in group B(P<0.05)28 d after the treatment and its improvement was quicker in group A (P<0.05),and the difference between the two groups was even more significant(P<0.01)at d 56.The SI in group A was higher than that in group B(P<0.05)at d 14 and this persisted until d 56 when the follow-up of this research was finished. CONCLUSION:Treatment of H pylori can enhance the efficacy of ferrous succinate therapy in IDA patients with H pylori-positive chronic gastritis.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第40期5380-5383,共4页 世界胃肠病学杂志(英文版)
关键词 H pylori Iron deficiency anemia Oral irontreatment Chronic gastritis 幽门螺杆菌 细菌感染 贫血 胃炎
  • 相关文献

参考文献1

二级参考文献28

  • 1Fennerty MB. Helicobacter pylori. Arch Intern Med 1994; 154: 721-727.
  • 2O'Connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol 1994; 201: 11-15.
  • 3Yamada T. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69.
  • 4Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996; 110: 1244-1252.
  • 5Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-708.
  • 6Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275: 622-629.
  • 7de Boer WA, Tytgat GN. Regular review: Treatment of Helicobacter pylori infection. BMJ 2000; 320: 31-34.
  • 8Peterson WL, Graham DY. Helicobacter pylori In: Feldman M, Scharschmidt BF, Sleisenger MH eds. Gastrointestinal and liver disease: Pathophysiology, diagnosis, management. 6th ed. Philadelphia: WB Saunders Pub 1998: 604-619.
  • 9Vaira D, Holton J, Menegatti M, Ricci C, Gatta L, Geminiani A, Miglioli M. Review article: Invasive and non-invasive tests for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 13-22.
  • 10Atherton JC, Spiller RC. The urea breath test for Helicobacter pylori. Gut 1994; 35: 723-725.

共引文献1

同被引文献50

引证文献7

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部